ClinicalTrials.gg
Not yet recruitingNCT07004075Updated Jun 4, 2025

FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

A Phase 3 interventional study of Luvometinib and Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide in Low-grade Glioma, Pediatric Low-grade Gliomas and pLGG With BRAF Alteration, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Study summary

An open-label, randomized, multi-center phase III clinical study: Aim to evaluate the efficacy and safety of FCN-159 monotherapy versus the treatment by investigator's choice in patients with pediatric low-grade glioma harboring KIAA1549-BRAF fusion or BRAF V600E mutation

02

Conditions studied

  • Low-grade Glioma
  • Pediatric Low-grade Gliomas
  • pLGG With BRAF Alteration
03

In context

Lead sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 35 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pediatric patients aged between ≥ 2 years and \< 18 years; regardless of male or female.
  2. and/or cytologically confirmed diagnosis of low-grade glioma (pLGG diagnosis as Grade 1 or 2 according to the 2021 WHO classification of CNS).
  3. KIAA1549-BRAF fusion or BRAF V600E mutation-positive.
  4. Patients requiring systemic therapy as determined by the investigator, including patients having disease recurrence or progression, or residual disease of surgery, or unresectable.
  5. At least one intracranial that can be reproducibly measured in two dimensions on T2-FLAIR, with the minimum size of the bi-perpendicular diameter of ≥ 10 mm, and can be visible on two or more imaging slice.
  1. performance score or Lansky performance score ≥ 70. 7.Adequate organ function within 14 days before enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously received any of the following treatments:

    1. Patients who have received chemotherapy drugs or traditional Chinese medicines or herbals with definitive anti-tumor treatment within 4 weeks preceding the first dose of drug;
    2. Patients who have received growth factors that promote or leukocyte count or function within 14 days preceding the first dose of investigational drug;
    3. Patients who received radiotherapy, surgery or immunotherapy within 4 weeks preceding the first dose of investigational drug;
    4. Patients who have participated in other interventional clinical trials within 4 weeks before receiving the first dose of investigational drug;
    5. Patients who have received within 4 weeks preceding the first dose of investigational drug, or patients who have received inactivated vaccines and mRNA vaccines within 14 days preceding the study treatment;
    6. Patients who have previously received any other MEK 1/2 inhibitors such as Selumetinib or BRAF inhibitors such as Dabrafenib.
  2. Patients with high-grade gliomas, as well as schwannoma, subependymal giant cell astrocytoma (tuberous sclerosis), and diffuse intrinsic pontine gliomas (even if the histological diagnosis is WHO Grade 1 or 2).
  3. Patients who require endotracheal intubation for assisted ventilation or tracheotomy should be excluded.
  4. Patients who have uncontrollable epilepsy as assessed by the investigator.
  5. Patients with dysphagia, active GI diseases, malabsorption syndrome, or other conditions that will interfere with the absorption of the investigational drug.
  6. Patients with active bacterial, fungal or viral infections, including virus surface antigen positive and hepatitis B virus DNA exceeding 1000 IU/ml. Hepatitis B carriers are allowed to be enrolled. Patients with positive virus (HCV) antibody test; those who have confirmed (HIV) infection, and are unwilling to undergo HIV testing.
  7. Patients with history or current evidence of retinal vein obstruction (RVO), retinal pigment epithelial detachment (RPED), central retinal vein occlusion, glaucoma, and other significant abnormalities in ophthalmological examinations.
  8. Interstitial pneumonia, including clinically significant radiation pneumonitis.
  9. Grade 3 creatine phosphokinase increased (>5 × - 10 × ULN).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Experimental arm: Luvometinib

    FCN-159, 5 mg/m\^2, once daily, continuous oral administration

    Drug: Luvometinib

  • Active comparator
    Comparator: investigator's choice of chemotherapy

    Chemotherapeutic Agent COG-V/C, intravenous solution for injection Carboplatin + Vindesine, intravenous solution for injection Carboplatin, intravenous solution for injection Temozolomide, orally Day 1 to Day 5 of each 28 days as a cycle

    Biological: Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide

Interventions

  • Luvometinib oral tablet

  • BiologicalChemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide

    Investigator's choice of chemotherapy administered IV or orally

06

What researchers measure

Primary outcomes

  1. Compare the progression free survival (PFS) of FCN-159 versus chemotherapy by IRC

    PFS assessed per RANO-LGG criteria by IRC, and defined as the time from randomization to the first recorded progressive disease or death from any cause, whichever is first

    Time frame: up to 48 months

Secondary outcomes

  1. PFS of FCN-159 versus chemotherapy by INV

    PFS assessed per RANO-LGG criteria by inverstigator

    Time frame: up to 48 months

  2. Objective response rate (ORR) of FCN-159 versus chemotherapy

    ORR assessed per RANO-LGG criteria,and defined as the proportion of patients with confirmed complete response (CR), partial response (PR) or minor response (MR)

    Time frame: up to 48 months

  3. Clinical benefit rate (CBR) of FCN-159 versus chemotherapy

    CBR is defined as the proportion of patients with confirmed CR, PR, MR and SD lasting ≥24 weeks as assessed based on the RANO-LGG criteria

    Time frame: up to 48 months

  4. Duration of overall response (DOR) of FCN-159 versus chemotherapy

    DOR is defined as the time from the date of the first CR, PR or MR to the first recorded tumor progression or death (death due to any cause), whichever occurs earlier

    Time frame: up to 48 months

  5. Time to response (TTR) of FCN-159 versus chemotherapy

    TTR is defined as the time from the first dose of the investigational drug to the first confirmed CR, PR or MR based on the RANO-LGG criteria

    Time frame: up to 48 months

  6. Overall survival (OS) of FCN-159 vesus chemotherapy

    OS is defined as the time from the first dose of the investigational drug to death by any cause

    Time frame: up to 48 months

  7. Safety of FCN-159 versus chemotherapy

    Number of Participants With Adverse Events (AEs) of treated participants

    Time frame: up to 48 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Apr 2027, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 4, 2025
StartEst.
Jun 30, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2029
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07004075
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Jun 30, 2025 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Jun 4, 2025

Study contacts

Wenbin Li
Contact
neure55@126.com
+86 1530137799
Zhuang Kang
Contact
kzhaoren1984@163.com
+86 15011281069

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luvometinib

Start the discussion